<?xml version='1.0' encoding='us-ascii'?>
<TimeML xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:noNamespaceSchemaLocation="http://timeml.org/timeMLdocs/TimeML_1.2.1.xsd">
<DOCID>20</DOCID>
<TEXT>
Exhibit . CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN <EVENT class="COREFERENCE" eid="e0">OMITTED</EVENT> BECAUSE ARTARA THERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE <EVENT class="COREFERENCE" eid="e1">HARM</EVENT> TO ARTARA THERAPEUTICS, INC. IF PUBLICLY DISCLOSED. SPONSORED RESEARCH AND LICENSE AGREEMENT This Sponsored Research and License Agreement (this "Agreement") is <EVENT class="COREFERENCE" eid="e2">entered</EVENT> into on November , (the "Effective Date "), by and between ArTara, Inc. located at Little West t h Street, New York, NY ("ArTara"), and The University of Iowa, located at c/o Division of Sponsored Programs, Gilmore Hall, Iowa City, IA ("University"). ArTara and University may individually be <EVENT class="COREFERENCE" eid="e3">referred</EVENT> to herein as a "Party," and collectively as "Parties." WI T N E S S E T H: WHEREAS, ArTara is <EVENT class="COREFERENCE" eid="e4">engaged</EVENT> in the <EVENT class="COREFERENCE" eid="e5">development</EVENT> of pharmaceutical products for the <EVENT class="COREFERENCE" eid="e6">treatment</EVENT> of serious rare diseases; WHEREAS, University is <EVENT class="COREFERENCE" eid="e7">engaged</EVENT> in clinical research to <EVENT class="COREFERENCE" eid="e8">improve</EVENT> the <EVENT class="COREFERENCE" eid="e9">diagnosis</EVENT> and <EVENT class="COREFERENCE" eid="e10">treatment</EVENT> of lymphangioma (LM) using OK- (as <EVENT class="COREFERENCE" eid="e11">defined</EVENT> below), a pharmaceutical product not <EVENT class="COREFERENCE" eid="e12">approved</EVENT> by regulatory authorities in the United States; WHEREAS, University is <EVENT class="COREFERENCE" eid="e13">engaged</EVENT> in a clinical research Program (as <EVENT class="COREFERENCE" eid="e14">defined</EVENT> below) and with Chugai Pharmaceutical Co., Ltd., - Nihonbashi -Chome, Chuo-ku, Tokyo, - Japan, and its wholly- <EVENT class="COREFERENCE" eid="e15">owned</EVENT> subsidiary, Chugai Pharma U.S.A, LLC Connell Drive, Suite , Berkeley Heights, New Jersey (collectively "Chugai"), the product manufacturer; WHEREAS, Principal Investigator (as <EVENT class="COREFERENCE" eid="e16">defined</EVENT> below) of the Program is an employee of the University and <EVENT class="COREFERENCE" eid="e17">holds</EVENT> the IND (as <EVENT class="COREFERENCE" eid="e18">defined</EVENT> below) <EVENT class="COREFERENCE" eid="e19">approved</EVENT> by the FDA (as <EVENT class="COREFERENCE" eid="e20">defined</EVENT> below) for OK- under BB-IND# ; WHEREAS, ArTara <EVENT class="COREFERENCE" eid="e21">wishes</EVENT> to <EVENT class="COREFERENCE" eid="e22">develop</EVENT> and <EVENT class="COREFERENCE" eid="e23">submit</EVENT> for regulatory <EVENT class="COREFERENCE" eid="e24">approval</EVENT> TARA- , a <EVENT class="COREFERENCE" eid="e25">proposed</EVENT> product that will be biosimilar to OK- ; WHEREAS, ArTara <EVENT class="COREFERENCE" eid="e26">wishes</EVENT> to <EVENT class="COREFERENCE" eid="e27">use</EVENT> the Program Data (as <EVENT class="COREFERENCE" eid="e28">defined</EVENT> below) <EVENT class="COREFERENCE" eid="e29">collected</EVENT> from the Program, <EVENT class="COREFERENCE" eid="e30">conduct</EVENT> <EVENT class="COREFERENCE" eid="e31">research</EVENT> analysis of the Data and potentially <EVENT class="COREFERENCE" eid="e32">rely</EVENT> on <EVENT class="COREFERENCE" eid="e33">said</EVENT> Program Data to <EVENT class="COREFERENCE" eid="e34">support</EVENT> <EVENT class="COREFERENCE" eid="e35">Regulatory</EVENT> Approvals (as <EVENT class="COREFERENCE" eid="e36">defined</EVENT> below) for TARA- in the Territory (as <EVENT class="COREFERENCE" eid="e37">defined</EVENT> below); and WHEREAS, the <EVENT class="COREFERENCE" eid="e38">copying</EVENT> <EVENT class="COREFERENCE" eid="e39">review</EVENT> and <EVENT class="COREFERENCE" eid="e40">analysis</EVENT> of Program Data for the <EVENT class="COREFERENCE" eid="e41">Project</EVENT> (as <EVENT class="COREFERENCE" eid="e42">defined</EVENT> below) <EVENT class="COREFERENCE" eid="e43">contemplated</EVENT> by this Agreement is of mutual interest and benefit to University and ArTara. NOW, THEREFORE, in consideration of the foregoing premises and the mutual <EVENT class="COREFERENCE" eid="e44">covenants</EVENT> and <EVENT class="COREFERENCE" eid="e45">agreements</EVENT> <EVENT class="COREFERENCE" eid="e46">contained</EVENT> herein, the Parties <EVENT class="COREFERENCE" eid="e47">agree</EVENT> as follows : ARTICLE ONE DEFINITIONS . "Affiliates" of a person or entity means any other entity which (directly or indirectly) is controlled by, controls or is under common control with such person or entity. For the purposes of this definition, the term "control" ( including , with correlative meanings, the terms " <EVENT class="COREFERENCE" eid="e48">controlled</EVENT> by" and "under common control with") as <EVENT class="COREFERENCE" eid="e49">used</EVENT> with respect to an entity will mean (i) in the case of a corporate entity, direct or indirect ownership of voting securities entitled to cast at least fifty percent ( %) of the votes in the <EVENT class="COREFERENCE" eid="e50">election</EVENT> of directors, or (ii) in the case of a non-corporate entity, direct or indirect ownership of at least fifty percent ( %) of the equity interests with the power to direct the <EVENT class="COREFERENCE" eid="e51">management</EVENT> and policies of such entity, provided that if local law restricts foreign ownership, control will be established by direct or indirect ownership of the maximum ownership percentage that may, under such local law, be owned by foreign interests. Source: ARTARA THERAPEUTICS, INC., -K, / / . "CRO" means a contract research organization selected by ArTara to assist in the <EVENT class="COREFERENCE" eid="e52">Project</EVENT> as approved by the University and/or Principal Investigator, such <EVENT class="COREFERENCE" eid="e53">approval</EVENT> not to be unreasonably delayed or withheld. . "FDA" means the United States Food and Drug Administration. . "<EVENT class="COREFERENCE" eid="e54">Field</EVENT> means all therapeutic, diagnostic and prophylactic <EVENT class="COREFERENCE" eid="e55">uses</EVENT> of the Product(s). . "First Commercial <EVENT class="COREFERENCE" eid="e56">Sale</EVENT> means the first <EVENT class="COREFERENCE" eid="e57">sale</EVENT> for <EVENT class="COREFERENCE" eid="e58">use</EVENT> or <EVENT class="COREFERENCE" eid="e59">consumption</EVENT> for which revenue has been recognized of Product in a country or territory after all required <EVENT class="COREFERENCE" eid="e60">Regulatory</EVENT> Approvals for commercial <EVENT class="COREFERENCE" eid="e61">sale</EVENT> of Product have been obtained in such country or territory. . "ICH-GCP's" means the International Conference on Harmonization and Good Clinical Practice Guidelines as adopted in the applicable FDA regulations. . "<EVENT class="COREFERENCE" eid="e62">Indication</EVENT> means <EVENT class="COREFERENCE" eid="e63">treatment</EVENT> of lymphangioma (also known as lymphatic malformations) in humans. . "IND" means University filed investigational new drug application on file with the FDA (BB-IND# ) for OK- for the <EVENT class="COREFERENCE" eid="e64">Indication</EVENT> . "Net Sales" means, with respect to the Product, the gross invoiced sales price payable to ArTara and/or its Affiliates and their respective licensees and sublicensees for <EVENT class="COREFERENCE" eid="e65">sales</EVENT> anywhere in the world of the Product to a third party, less: (a) <EVENT class="COREFERENCE" eid="e66">discounts</EVENT> (including cash, quantity and patient program discounts), retroactive <EVENT class="COREFERENCE" eid="e67">price</EVENT> reductions, <EVENT class="COREFERENCE" eid="e68">charge</EVENT> back payments and <EVENT class="COREFERENCE" eid="e69">rebates</EVENT> granted to managed health care organizations or to federal, state and local governments, their agencies, and purchasers and reimbursers or to trade customers; (b) credits or allowances actually, not to exceed the original invoice amount, granted upon <EVENT class="COREFERENCE" eid="e70">claims</EVENT> damaged goods, <EVENT class="COREFERENCE" eid="e71">rejections</EVENT> or <EVENT class="COREFERENCE" eid="e72">returns</EVENT> of the Product, including the Product returned in connection with <EVENT class="COREFERENCE" eid="e73">recalls</EVENT> or <EVENT class="COREFERENCE" eid="e74">withdrawals</EVENT> (c) freight out, postage, shipping and insurance charges for <EVENT class="COREFERENCE" eid="e75">delivery</EVENT> of the Product if charged separately and include in the gross receipts; and (d) taxes or duties, excluding income taxes and value-added taxes, levied on, absorbed or otherwise imposed on the <EVENT class="COREFERENCE" eid="e76">sale</EVENT> of the Product, including governmental charges otherwise imposed upon the billed amount, as adjusted for <EVENT class="COREFERENCE" eid="e77">rebates</EVENT> and <EVENT class="COREFERENCE" eid="e78">refunds</EVENT> provided that such are included in gross receipts and are paid to and/or its Affiliates and their respective licensees and sublicensees. Source: ARTARA THERAPEUTICS, INC., -K, / / Net Sales shall be <EVENT class="COREFERENCE" eid="e79">determined</EVENT> in accordance with generally <EVENT class="COREFERENCE" eid="e80">accepted</EVENT> accounting principles, consistently <EVENT class="COREFERENCE" eid="e81">applied</EVENT> . . "OK- " means Picibanil (OK- ), a lyophilized mixture of group A Streptococcus pyogenes developed by Chugai and that has been approved by applicable Japanese pharmaceutical regulatory authorities for the <EVENT class="COREFERENCE" eid="e82">treatment</EVENT> of the <EVENT class="COREFERENCE" eid="e83">Indication</EVENT> . "Principal Investigator" means Richard Smith, MD . "Product" shall mean TARA- and any similar products. . "<EVENT class="COREFERENCE" eid="e84">Program</EVENT> means collectively, the clinical research <EVENT class="COREFERENCE" eid="e85">studies</EVENT> investigating the efficacy and safety of OK- for the <EVENT class="COREFERENCE" eid="e86">Indication</EVENT> conducted by Principal Investigator in collaboration with multiple sites in the United States and the University expanded access program performed by Principal Investigator designed to improve the <EVENT class="COREFERENCE" eid="e87">diagnosis</EVENT> and <EVENT class="COREFERENCE" eid="e88">treatment</EVENT> of the <EVENT class="COREFERENCE" eid="e89">Indication</EVENT> using OK- . . "Program Data" means the data set forth on Exhibit A including all case reports forms, source data, and safety data in the possession of or available to University arising from the Program and any other data and information included in the IND. . "<EVENT class="COREFERENCE" eid="e90">Project</EVENT> shall mean the <EVENT class="COREFERENCE" eid="e91">compilation</EVENT> and available statistical <EVENT class="COREFERENCE" eid="e92">analyses</EVENT> of the Program Data as described in the Project Plan, which is summarized in Section . . . "Project Documentation" shall mean the documentation created and generated by ArTara and CRO in the <EVENT class="COREFERENCE" eid="e93">conduct</EVENT> of the <EVENT class="COREFERENCE" eid="e94">Project</EVENT> that incorporates or is based upon Program Data. . "Project Plan" means the plan for the <EVENT class="COREFERENCE" eid="e95">Project</EVENT> mutually agreed upon by the Parties as summarized in Section . . . "Right of Reference" means the authority to rely upon, and otherwise use, an <EVENT class="COREFERENCE" eid="e96">investigation</EVENT> for the purpose of obtaining <EVENT class="COREFERENCE" eid="e97">Regulatory</EVENT> Approvals, including the ability to make available the underlying raw (source) data from the <EVENT class="COREFERENCE" eid="e98">investigation</EVENT> for audit, if necessary. . "<EVENT class="COREFERENCE" eid="e99">Regulatory</EVENT> Approvals" means the medical, technical and scientific <EVENT class="COREFERENCE" eid="e100">licenses</EVENT> <EVENT class="COREFERENCE" eid="e101">registrations</EVENT> <EVENT class="COREFERENCE" eid="e102">authorizations</EVENT> and <EVENT class="COREFERENCE" eid="e103">approvals</EVENT> (including without limitation, <EVENT class="COREFERENCE" eid="e104">approvals</EVENT> of IND's, New Drug Applications ("NDA's") and <EVENT class="COREFERENCE" eid="e105">equivalents</EVENT> <EVENT class="COREFERENCE" eid="e106">supplements</EVENT> and <EVENT class="COREFERENCE" eid="e107">amendments</EVENT> <EVENT class="COREFERENCE" eid="e108">pre</EVENT> and post- approvals, <EVENT class="COREFERENCE" eid="e109">pricing</EVENT> and third-party reimbursements approvals and <EVENT class="COREFERENCE" eid="e110">labeling</EVENT> approvals) for the <EVENT class="COREFERENCE" eid="e111">development</EVENT> and <EVENT class="COREFERENCE" eid="e112">commercialization</EVENT> of pharmaceutical products. . "Regulatory Authorities" means any applicable national, regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity, necessary for the <EVENT class="COREFERENCE" eid="e113">development</EVENT> <EVENT class="COREFERENCE" eid="e114">manufacture</EVENT> <EVENT class="COREFERENCE" eid="e115">distribution</EVENT> <EVENT class="COREFERENCE" eid="e116">marketing</EVENT> <EVENT class="COREFERENCE" eid="e117">promotion</EVENT> <EVENT class="COREFERENCE" eid="e118">offer</EVENT> for sale, <EVENT class="COREFERENCE" eid="e119">use</EVENT> <EVENT class="COREFERENCE" eid="e120">import</EVENT> <EVENT class="COREFERENCE" eid="e121">export</EVENT> or <EVENT class="COREFERENCE" eid="e122">sale</EVENT> of a pharmaceutical product in a regulatory jurisdiction. . "Regulatory Filings" means collectively, IND's, Product License Applications, Drug Master Files, NDA's, Biological License Applications ("BLAs") including supportive and annual filings and/or any other equivalent or comparable filings as may be required by Regulatory Authorities to obtain <EVENT class="COREFERENCE" eid="e123">Regulatory</EVENT> Approvals. . "Royalty" means the royalty on Net Sales of Product in the <EVENT class="COREFERENCE" eid="e124">Indication</EVENT> as set forth in Article Three below. Source: ARTARA THERAPEUTICS, INC., -K, / / . "TARA- " means the ArTara pharmaceutical product intended to be similar to or biosimilar to OK- . . "Territory" means worldwide. ARTICLE TWO PROJECT . Performance of Project. The University and/or Principal Investigator together with ArTara and the CRO will <EVENT class="COREFERENCE" eid="e125">conduct</EVENT> the <EVENT class="COREFERENCE" eid="e126">Project</EVENT> in accordance with the Project Plan and will <EVENT class="COREFERENCE" eid="e127">use</EVENT> all reasonable <EVENT class="COREFERENCE" eid="e128">endeavors</EVENT> consistent with their expertise to successfully <EVENT class="COREFERENCE" eid="e129">complete</EVENT> the <EVENT class="COREFERENCE" eid="e130">Project</EVENT> It is the goal of the <EVENT class="COREFERENCE" eid="e131">Project</EVENT> to <EVENT class="COREFERENCE" eid="e132">use</EVENT> the Program Data as clinical support for Product Regulatory Filings and to <EVENT class="COREFERENCE" eid="e133">gain</EVENT> approval to <EVENT class="COREFERENCE" eid="e134">commercialize</EVENT> the Product for the <EVENT class="COREFERENCE" eid="e135">Indication</EVENT> in the Territory. . Project Plan. The Project Plan as <EVENT class="COREFERENCE" eid="e136">approved</EVENT> by each of the Parties may be <EVENT class="COREFERENCE" eid="e137">modified</EVENT> or <EVENT class="COREFERENCE" eid="e138">amended</EVENT> only upon mutual <EVENT class="COREFERENCE" eid="e139">agreement</EVENT> of each of the Parties. The <EVENT class="COREFERENCE" eid="e140">Project</EVENT> will <EVENT class="COREFERENCE" eid="e141">consist</EVENT> of three <EVENT class="COREFERENCE" eid="e142">phases</EVENT> (a) <EVENT class="COREFERENCE" eid="e143">Phase</EVENT> I: University and/or Principal Investigator will <EVENT class="COREFERENCE" eid="e144">provide</EVENT> access to the Program Data to ArTara and the CRO at the University's facilities. ArTara and the CRO will be <EVENT class="COREFERENCE" eid="e145">allowed</EVENT> to <EVENT class="COREFERENCE" eid="e146">make</EVENT> complete copies of the original Program Data for the purposes of off-site data <EVENT class="COREFERENCE" eid="e147">entry</EVENT> and <EVENT class="COREFERENCE" eid="e148">storage</EVENT> all as and only to the extent <EVENT class="COREFERENCE" eid="e149">needed</EVENT> to <EVENT class="COREFERENCE" eid="e150">support</EVENT> ArTara's <EVENT class="COREFERENCE" eid="e151">efforts</EVENT> to <EVENT class="COREFERENCE" eid="e152">accomplish</EVENT> the <EVENT class="COREFERENCE" eid="e153">Project</EVENT> University will <EVENT class="COREFERENCE" eid="e154">provide</EVENT> ArTara and CRO the <EVENT class="COREFERENCE" eid="e155">opportunity</EVENT> to <EVENT class="COREFERENCE" eid="e156">examine</EVENT> the originals of medical records and supporting records for the Program Data at the University during normal business hours and at mutually agreeable times. University and Principal Investigator will also <EVENT class="COREFERENCE" eid="e157">provide</EVENT> to ArTara contact information for other participating investigators and research sites that have <EVENT class="COREFERENCE" eid="e158">contributed</EVENT> data to the Program. University will <EVENT class="COREFERENCE" eid="e159">retain</EVENT> all Program Data for the sooner to <EVENT class="COREFERENCE" eid="e160">occur</EVENT> of a New Drug Application (NDA) for the Product being <EVENT class="COREFERENCE" eid="e161">approved</EVENT> or ten ( ) years from the Effective Date . ArTara will <EVENT class="COREFERENCE" eid="e162">bear</EVENT> any costs <EVENT class="COREFERENCE" eid="e163">related</EVENT> to necessary long- term on or off-site <EVENT class="COREFERENCE" eid="e164">storage</EVENT> of the Program Data, medical records and/or supporting records. ArTara <EVENT class="COREFERENCE" eid="e165">understands</EVENT> that separate engagement <EVENT class="COREFERENCE" eid="e166">agreements</EVENT> may be <EVENT class="COREFERENCE" eid="e167">required</EVENT> by collaborating third party entities and <EVENT class="COREFERENCE" eid="e168">associated</EVENT> principal investigators and University will <EVENT class="COREFERENCE" eid="e169">assist</EVENT> ArTara in obtaining such <EVENT class="COREFERENCE" eid="e170">agreements</EVENT> It is <EVENT class="COREFERENCE" eid="e171">understood</EVENT> that the goal of <EVENT class="COREFERENCE" eid="e172">Phase</EVENT> I is a feasibility <EVENT class="COREFERENCE" eid="e173">analysis</EVENT> of the Program Data to <EVENT class="COREFERENCE" eid="e174">support</EVENT> Regulatory Filings in the United States. (b) <EVENT class="COREFERENCE" eid="e175">Phase</EVENT> II: University <EVENT class="COREFERENCE" eid="e176">recognizes</EVENT> that because of ArTara's unfamiliarity with the Program Data database, <EVENT class="COREFERENCE" eid="e177">assistance</EVENT> from the Principal Investigator and other research and medical employees of the University may from time to time be <EVENT class="COREFERENCE" eid="e178">needed</EVENT> for ArTara to <EVENT class="COREFERENCE" eid="e179">query</EVENT> and <EVENT class="COREFERENCE" eid="e180">analyze</EVENT> the Program Data database as <EVENT class="COREFERENCE" eid="e181">needed</EVENT> to <EVENT class="COREFERENCE" eid="e182">achieve</EVENT> successful <EVENT class="COREFERENCE" eid="e183">presentation</EVENT> to applicable Regulatory Authorities and <EVENT class="COREFERENCE" eid="e184">submission</EVENT> of Regulatory Filings. ArTara will <EVENT class="COREFERENCE" eid="e185">endeavor</EVENT> to <EVENT class="COREFERENCE" eid="e186">minimize</EVENT> University resources <EVENT class="COREFERENCE" eid="e187">required</EVENT> during <EVENT class="COREFERENCE" eid="e188">Phase</EVENT> II. The goal of <EVENT class="COREFERENCE" eid="e189">Phase</EVENT> II will be to <EVENT class="COREFERENCE" eid="e190">compile</EVENT> the Project Documentation. (c) <EVENT class="COREFERENCE" eid="e191">Phase</EVENT> III: CRO will <EVENT class="COREFERENCE" eid="e192">convert</EVENT> Program Data to eCTD format for <EVENT class="COREFERENCE" eid="e193">submission</EVENT> to Regulatory Authorities. University <EVENT class="COREFERENCE" eid="e194">recognizes</EVENT> that ArTara may <EVENT class="COREFERENCE" eid="e195">receive</EVENT> specific data <EVENT class="COREFERENCE" eid="e196">requests</EVENT> from Regulatory Authorities in connection with ArTara's <EVENT class="COREFERENCE" eid="e197">presentations</EVENT> of Program Data to <EVENT class="COREFERENCE" eid="e198">support</EVENT> Regulatory Filings. University will <EVENT class="COREFERENCE" eid="e199">assist</EVENT> ArTara in responding to such <EVENT class="COREFERENCE" eid="e200">requests</EVENT> for data or access to <EVENT class="COREFERENCE" eid="e201">source</EVENT> data from Regulatory Authorities. ArTara <EVENT class="COREFERENCE" eid="e202">agrees</EVENT> to <EVENT class="COREFERENCE" eid="e203">notify</EVENT> University of such <EVENT class="COREFERENCE" eid="e204">requests</EVENT> as soon as is practicable. The goal of <EVENT class="COREFERENCE" eid="e205">Phase</EVENT> III will be <EVENT class="COREFERENCE" eid="e206">filing</EVENT> of a BLA <EVENT class="COREFERENCE" eid="e207">based</EVENT> on Project Documentation and <EVENT class="COREFERENCE" eid="e208">response</EVENT> to Regulatory Authorities. Source: ARTARA THERAPEUTICS, INC., -K, / / (d) <EVENT class="COREFERENCE" eid="e209">Phase</EVENT> IV Optional: Upon mutual <EVENT class="COREFERENCE" eid="e210">written</EVENT> agreement of University and ArTara, ArTara may <EVENT class="COREFERENCE" eid="e211">sponsor</EVENT> , and University may <EVENT class="COREFERENCE" eid="e212">conduct</EVENT> , new Product or Product- <EVENT class="COREFERENCE" eid="e213">related</EVENT> clinical <EVENT class="COREFERENCE" eid="e214">studies</EVENT> <EVENT class="COREFERENCE" eid="e215">studies</EVENT> (for example, follow -up <EVENT class="COREFERENCE" eid="e216">studies</EVENT> <EVENT class="COREFERENCE" eid="e217">studies</EVENT> to <EVENT class="COREFERENCE" eid="e218">support</EVENT> the goal of the <EVENT class="COREFERENCE" eid="e219">Project</EVENT> or as may be useful for gaining or maintaining <EVENT class="COREFERENCE" eid="e220">Regulatory</EVENT> Approvals for the Product for the <EVENT class="COREFERENCE" eid="e221">Indication</EVENT> Any such <EVENT class="COREFERENCE" eid="e222">studies</EVENT> will be at the sole discretion of each Party subject to terms and conditions to be mutually <EVENT class="COREFERENCE" eid="e223">agreed</EVENT> upon in <EVENT class="COREFERENCE" eid="e224">agreements</EVENT> separate from this Agreement. Richard Smith, MD will be <EVENT class="COREFERENCE" eid="e225">given</EVENT> first consideration as a principal investigator for all new Product or Product- related clinical <EVENT class="COREFERENCE" eid="e226">studies</EVENT> in addition to other sites <EVENT class="COREFERENCE" eid="e227">provided</EVENT> final site <EVENT class="COREFERENCE" eid="e228">selection</EVENT> will be <EVENT class="COREFERENCE" eid="e229">based</EVENT> on the best interest of the <EVENT class="COREFERENCE" eid="e230">Project</EVENT> (e) <EVENT class="COREFERENCE" eid="e231">Phase</EVENT> V: Publication: <EVENT class="COREFERENCE" eid="e232">Collected</EVENT> data from the <EVENT class="COREFERENCE" eid="e233">Project</EVENT> will be <EVENT class="COREFERENCE" eid="e234">used</EVENT> to <EVENT class="COREFERENCE" eid="e235">write</EVENT> a paper by the University and/or Principal Investigator (the "<EVENT class="COREFERENCE" eid="e236">Publication</EVENT> ) as a follow up to the <EVENT class="COREFERENCE" eid="e237">publication</EVENT> in (Smith MC, Zimmerman MB, Burke DK, Bauman NM, Sato Y, Smith RJ; OK- Collaborative Study Group. Efficacy and safety of OK- immunotherapy of lymphatic malformations. Laryngoscope. Jan; ( ): - . doi: . /lary. . PubMed PMID: ) . ( the "<EVENT class="COREFERENCE" eid="e238">Publication</EVENT> ). The <EVENT class="COREFERENCE" eid="e239">Publication</EVENT> will be in accordance with the terms in Article herein. . Project Management. During the term of this Agreement, the Principal Investigator and and/or his authorized representative and ArTara <EVENT class="COREFERENCE" eid="e240">authorized</EVENT> representatives will <EVENT class="COREFERENCE" eid="e241">meet</EVENT> as necessary to <EVENT class="COREFERENCE" eid="e242">consult</EVENT> with one another and <EVENT class="COREFERENCE" eid="e243">discuss</EVENT> the progress and results of the <EVENT class="COREFERENCE" eid="e244">Project</EVENT> and any <EVENT class="COREFERENCE" eid="e245">modifications</EVENT> to the Project Plan. <EVENT class="COREFERENCE" eid="e246">Consultation</EVENT> by either Party shall be by means of personal <EVENT class="COREFERENCE" eid="e247">visits</EVENT> <EVENT class="COREFERENCE" eid="e248">correspondence</EVENT> and telephone <EVENT class="COREFERENCE" eid="e249">calls</EVENT> all as appear reasonable and necessary and are mutually agreed upon by the Principal Investigator and ArTara. ARTICLE THREE FUNDING AND PAYMENT . Funding. During the term of the <EVENT class="COREFERENCE" eid="e250">Project</EVENT> in accordance with the Project Plan, ArTara will <EVENT class="COREFERENCE" eid="e251">provide</EVENT> thirty thousand dollars (US $ , ) per year in funding for the <EVENT class="COREFERENCE" eid="e252">Project</EVENT> taking into consideration the time <EVENT class="COREFERENCE" eid="e253">spent</EVENT> by University employees <EVENT class="COREFERENCE" eid="e254">required</EVENT> for the <EVENT class="COREFERENCE" eid="e255">Project</EVENT> The Parties <EVENT class="COREFERENCE" eid="e256">agree</EVENT> to <EVENT class="COREFERENCE" eid="e257">discuss</EVENT> in good faith potential additional funding <EVENT class="COREFERENCE" eid="e258">required</EVENT> for <EVENT class="COREFERENCE" eid="e259">completion</EVENT> of the Project as applicable and necessary. . Approval Milestone <EVENT class="COREFERENCE" eid="e260">based</EVENT> on Data Value: Within forty-five ( ) days of an <EVENT class="COREFERENCE" eid="e261">approval</EVENT> of the TARA- BLA by the FDA, ArTara will <EVENT class="COREFERENCE" eid="e262">pay</EVENT> a one- time approval milestone to University pursuant to the usefulness of the Program Data in TARA- 's BLA filing, as set forth below: Official Feedback from FDA regarding the Program Data Milestone [***] $[***] [***] $[***] [***] $[***] [***] [***] Source: ARTARA THERAPEUTICS, INC., -K, / / . Royalties. Royalties will be payable by ArTara on Net Sales of Product in the <EVENT class="COREFERENCE" eid="e263">Indication</EVENT> ArTara will, no later than [***] following the <EVENT class="COREFERENCE" eid="e264">close</EVENT> of each calendar quarter, <EVENT class="COREFERENCE" eid="e265">pay</EVENT> tiered Royalties <EVENT class="COREFERENCE" eid="e266">based</EVENT> on annual Net Sales of Product in the <EVENT class="COREFERENCE" eid="e267">Indication</EVENT> as set forth below: Annual Net Sales of Product for the <EVENT class="COREFERENCE" eid="e268">Indication</EVENT> Annual Royalty Rate Percent Net Sales $ - $ , , . % >$ , , - $ , , . % >$ , , . % . Royalty Reduction. In the event the Regulatory Authorities <EVENT class="COREFERENCE" eid="e269">determine</EVENT> that the Program Data is not sufficient for <EVENT class="COREFERENCE" eid="e270">Regulatory</EVENT> Approvals on its own and additional pediatric efficacy and safety clinical studies are <EVENT class="COREFERENCE" eid="e271">required</EVENT> , Royalties set forth above will be <EVENT class="COREFERENCE" eid="e272">reduced</EVENT> by [***] percent ([ ***]%). . Sales Milestone Payments. In the event that Annual Net Sales, as <EVENT class="COREFERENCE" eid="e273">detailed</EVENT> in Section . , <EVENT class="COREFERENCE" eid="e274">surpass</EVENT> certain thresholds, ArTara will <EVENT class="COREFERENCE" eid="e275">make</EVENT> the following <EVENT class="COREFERENCE" eid="e276">payments</EVENT> <EVENT class="COREFERENCE" eid="e277">payments</EVENT> no later than [***] following the <EVENT class="COREFERENCE" eid="e278">close</EVENT> of the calendar quarter in which each milestone is <EVENT class="COREFERENCE" eid="e279">reached</EVENT> as set forth below: Annual Net Sales of Product for the <EVENT class="COREFERENCE" eid="e280">Indication</EVENT> <EVENT class="COREFERENCE" eid="e281">Exceeds</EVENT> Milestone Payment $ , , $ , $ , , $ , $ , , $ , . Payments.
</TEXT>
<MAKEINSTANCE aspect="NONE" eiid="ei4863" eventID="e0" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4864" eventID="e1" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4865" eventID="e2" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4866" eventID="e3" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4867" eventID="e4" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4868" eventID="e5" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4869" eventID="e6" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4870" eventID="e7" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4871" eventID="e8" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4872" eventID="e9" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4873" eventID="e10" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4874" eventID="e11" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4875" eventID="e12" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4876" eventID="e13" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4877" eventID="e14" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4878" eventID="e15" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4879" eventID="e16" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4880" eventID="e17" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4881" eventID="e18" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4882" eventID="e19" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4883" eventID="e20" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4884" eventID="e21" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4885" eventID="e22" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4886" eventID="e23" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4887" eventID="e24" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4888" eventID="e25" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4889" eventID="e26" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4890" eventID="e27" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4891" eventID="e28" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4892" eventID="e29" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4893" eventID="e30" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4894" eventID="e31" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4895" eventID="e32" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4896" eventID="e33" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4897" eventID="e34" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4898" eventID="e35" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4899" eventID="e36" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4900" eventID="e37" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4901" eventID="e38" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4902" eventID="e39" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4903" eventID="e40" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4904" eventID="e41" polarity="POS" pos="PROPN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4905" eventID="e42" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4906" eventID="e43" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4907" eventID="e44" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4908" eventID="e45" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4909" eventID="e46" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4910" eventID="e47" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4911" eventID="e48" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4912" eventID="e49" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4913" eventID="e50" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4914" eventID="e51" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4915" eventID="e52" polarity="POS" pos="PROPN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4916" eventID="e53" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4917" eventID="e54" polarity="POS" pos="PROPN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4918" eventID="e55" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4919" eventID="e56" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4920" eventID="e57" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4921" eventID="e58" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4922" eventID="e59" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4923" eventID="e60" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4924" eventID="e61" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4925" eventID="e62" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4926" eventID="e63" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4927" eventID="e64" polarity="POS" pos="PROPN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4928" eventID="e65" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4929" eventID="e66" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4930" eventID="e67" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4931" eventID="e68" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4932" eventID="e69" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4933" eventID="e70" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4934" eventID="e71" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4935" eventID="e72" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4936" eventID="e73" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4937" eventID="e74" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4938" eventID="e75" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4939" eventID="e76" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4940" eventID="e77" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4941" eventID="e78" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4942" eventID="e79" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4943" eventID="e80" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4944" eventID="e81" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4945" eventID="e82" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4946" eventID="e83" polarity="POS" pos="PROPN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4947" eventID="e84" polarity="POS" pos="PROPN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4948" eventID="e85" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4949" eventID="e86" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4950" eventID="e87" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4951" eventID="e88" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4952" eventID="e89" polarity="POS" pos="PROPN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4953" eventID="e90" polarity="POS" pos="PROPN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4954" eventID="e91" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4955" eventID="e92" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4956" eventID="e93" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4957" eventID="e94" polarity="POS" pos="PROPN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4958" eventID="e95" polarity="POS" pos="PROPN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4959" eventID="e96" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4960" eventID="e97" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4961" eventID="e98" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4962" eventID="e99" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4963" eventID="e100" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4964" eventID="e101" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4965" eventID="e102" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4966" eventID="e103" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4967" eventID="e104" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4968" eventID="e105" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4969" eventID="e106" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4970" eventID="e107" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4971" eventID="e108" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4972" eventID="e109" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4973" eventID="e110" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4974" eventID="e111" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4975" eventID="e112" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4976" eventID="e113" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4977" eventID="e114" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4978" eventID="e115" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4979" eventID="e116" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4980" eventID="e117" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4981" eventID="e118" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4982" eventID="e119" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4983" eventID="e120" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4984" eventID="e121" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4985" eventID="e122" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4986" eventID="e123" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4987" eventID="e124" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4988" eventID="e125" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4989" eventID="e126" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4990" eventID="e127" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4991" eventID="e128" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4992" eventID="e129" polarity="POS" pos="ADJECTIVE" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4993" eventID="e130" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4994" eventID="e131" polarity="POS" pos="PROPN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4995" eventID="e132" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4996" eventID="e133" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4997" eventID="e134" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4998" eventID="e135" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei4999" eventID="e136" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5000" eventID="e137" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5001" eventID="e138" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5002" eventID="e139" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5003" eventID="e140" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5004" eventID="e141" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5005" eventID="e142" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5006" eventID="e143" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5007" eventID="e144" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5008" eventID="e145" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5009" eventID="e146" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5010" eventID="e147" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5011" eventID="e148" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5012" eventID="e149" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5013" eventID="e150" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5014" eventID="e151" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5015" eventID="e152" polarity="POS" pos="ADJECTIVE" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5016" eventID="e153" polarity="POS" pos="PROPN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5017" eventID="e154" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5018" eventID="e155" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5019" eventID="e156" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5020" eventID="e157" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5021" eventID="e158" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5022" eventID="e159" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5023" eventID="e160" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5024" eventID="e161" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5025" eventID="e162" polarity="POS" pos="PROPN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5026" eventID="e163" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5027" eventID="e164" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5028" eventID="e165" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5029" eventID="e166" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5030" eventID="e167" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5031" eventID="e168" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5032" eventID="e169" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5033" eventID="e170" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5034" eventID="e171" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5035" eventID="e172" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5036" eventID="e173" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5037" eventID="e174" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5038" eventID="e175" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5039" eventID="e176" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5040" eventID="e177" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5041" eventID="e178" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5042" eventID="e179" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5043" eventID="e180" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5044" eventID="e181" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5045" eventID="e182" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5046" eventID="e183" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5047" eventID="e184" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5048" eventID="e185" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5049" eventID="e186" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5050" eventID="e187" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5051" eventID="e188" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5052" eventID="e189" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5053" eventID="e190" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5054" eventID="e191" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5055" eventID="e192" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5056" eventID="e193" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5057" eventID="e194" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5058" eventID="e195" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5059" eventID="e196" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5060" eventID="e197" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5061" eventID="e198" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5062" eventID="e199" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5063" eventID="e200" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5064" eventID="e201" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5065" eventID="e202" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5066" eventID="e203" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5067" eventID="e204" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5068" eventID="e205" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5069" eventID="e206" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5070" eventID="e207" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5071" eventID="e208" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5072" eventID="e209" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5073" eventID="e210" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5074" eventID="e211" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5075" eventID="e212" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5076" eventID="e213" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5077" eventID="e214" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5078" eventID="e215" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5079" eventID="e216" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5080" eventID="e217" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5081" eventID="e218" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5082" eventID="e219" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5083" eventID="e220" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5084" eventID="e221" polarity="POS" pos="PROPN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5085" eventID="e222" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5086" eventID="e223" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5087" eventID="e224" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5088" eventID="e225" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5089" eventID="e226" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5090" eventID="e227" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5091" eventID="e228" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5092" eventID="e229" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5093" eventID="e230" polarity="POS" pos="PROPN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5094" eventID="e231" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5095" eventID="e232" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5096" eventID="e233" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5097" eventID="e234" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5098" eventID="e235" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5099" eventID="e236" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5100" eventID="e237" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5101" eventID="e238" polarity="POS" pos="PROPN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5102" eventID="e239" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5103" eventID="e240" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5104" eventID="e241" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5105" eventID="e242" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5106" eventID="e243" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5107" eventID="e244" polarity="POS" pos="PROPN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5108" eventID="e245" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5109" eventID="e246" polarity="POS" pos="PROPN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5110" eventID="e247" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5111" eventID="e248" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5112" eventID="e249" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5113" eventID="e250" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5114" eventID="e251" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5115" eventID="e252" polarity="POS" pos="PROPN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5116" eventID="e253" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5117" eventID="e254" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5118" eventID="e255" polarity="POS" pos="PROPN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5119" eventID="e256" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5120" eventID="e257" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5121" eventID="e258" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5122" eventID="e259" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5123" eventID="e260" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5124" eventID="e261" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5125" eventID="e262" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5126" eventID="e263" polarity="POS" pos="PROPN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5127" eventID="e264" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5128" eventID="e265" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5129" eventID="e266" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5130" eventID="e267" polarity="POS" pos="PROPN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5131" eventID="e268" polarity="POS" pos="PROPN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5132" eventID="e269" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5133" eventID="e270" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5134" eventID="e271" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5135" eventID="e272" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5136" eventID="e273" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5137" eventID="e274" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5138" eventID="e275" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5139" eventID="e276" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5140" eventID="e277" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5141" eventID="e278" polarity="POS" pos="NOUN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5142" eventID="e279" polarity="POS" pos="VERB" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5143" eventID="e280" polarity="POS" pos="PROPN" tense="NONE" />
<MAKEINSTANCE aspect="NONE" eiid="ei5144" eventID="e281" polarity="POS" pos="NOUN" tense="NONE" />
</TimeML>